Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) (ACTRN12621000187842)
DAPA_HF
This trial is No longer recruiting
Registration number ACTRN12621000187842
Program & service
This trial is being run with the Heart & Lung service, and as part of the Cardiology program.
Trial phase
Other
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor David Kaye
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR